Clinical trial

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

NCT01156311

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-06-01

PhasePHASE2

Study timeline

Study start (unknown)2010-06-01Date precision: month

Registry last updated2017-03-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing-Remitting Multiple Sclerosisverified · MONDO: relapsing-remitting multiple sclerosis

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

dimethyl fumarateDRUG · verified · RxNorm: dimethyl fumarate

Sponsors & collaborators

Biogenlead sponsor

Mapped research locations

BostonMassachusetts, United States1 BaltimoreMaryland, United States1 AtlantaGeorgia, United States1 ClevelandOhio, United States1 PortlandOregon, United States1 PhoenixArizona, United States1 MilwaukeeWisconsin, United States1 DaytonOhio, United States1 Fort WayneIndiana, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01156311 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.